menu
    • menu

    Company profile for Lupin Manufacturing Solutions

    Mix Gif-PSE
    News
    Lupin Pharma's Manufacturing Arm Expands Dabhasa Facility

    20 Mar 2026

    // PRESS RELEASE

    Lupin Manufacturing Solutions partners with PolyPeptide

    12 Dec 2025

    // PRESS RELEASE

    Lupin Unit Expands CDMO Business With Oncology Block In Vizag

    12 Nov 2025

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    #1

    Contact Supplier

    Website

    CPhI North America

    Exhibiting

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    speak-pharma/we-re-investing-in-next-gen-cdmo-peptide-building-blocks-infrastructure-to-support-the-evolving-demands-of-complex-therapies

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    Key Products KEY PRODUCTS

    SERVICES

    Key Products KEY SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Related CompaniesRelated Companies

    About

    Lupin Manufacturing Solutions (LMS), a wholly owned Lupin subsidiary, offers high-quality APIs and end-to-end CDMO services from R&D to commercial scale. Backed by five decades of pharma expertise, LMS combines cost efficiency with regulatory excellence. With world-class sites in Dabhasa and Vizag, and an R&D center in Pune, we deliver integrated, sustainable, and globally compliant solutions that accelerate drug development and reduce environmental impact. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Lupin Manufacturing Solutionsindia-flag Flag
    Country
    Country
    India
    Address
    Address
    2nd Floor, Block 12, 13, 14, Art Guild House Wing B, Phoenix Mall, LBS Marg, ...
    Telephone
    Telephone
    +91 2266402323
    Client Email
    Email
    lmsinfo@lupin.com
    Client Website
    Website
    https://www.lmscdmo.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/lupin-manufacturing-solutions/
    youtube
    YouTube
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI North America

    Exhibiting

    envelop Contact Supplier

    CPhI North America

    Contact Supplier

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    INTERVIEW #SpeakPharma

    read-more
    read-more
    “We’re investing in next-gen CDMO & peptide building blocks infrastructure to support the evolving demands of complex therapies.”

    mic“We’re investing in next-gen CDMO & peptide building blocks infrastructure to support the evolving demands of complex therapies.”

    This week, SpeakPharma interviews Dr. Abdelaziz Toumi, Chief Executive Officer of Lupin Manufacturing Solutions (LMS). In this exclusive interview with PharmaCompass, Dr. Toumi discusses the evolving CDMO landscape, the shift toward complex therapies and growing peptide ecosystems along with LMS’s recent strategic investments in integrated CDMO and peptide building blocks infrastructure. As the industry convenes at DCAT Week, he highlights how LMS is positioning itself as a capability-driven CDMO partner for next-gen complex therapies.Dr. Toumi, The US has been taking several steps to reduce dependence on overseas pharmaceutical supply chains. How is Lupin Manufacturing Solutions (LMS) navigating these shifts?The framing of this debate as globalization versus reshoring misses what is actually happening. What we are seeing is a deliberate recalibration, a move from networks built purely for cost efficiency toward architectures that distribute risk more intelligently. That is a fundamentally different objective, and it changes what pharmaceutical companies expect from their manufacturing partners. What policymakers are pushing for, whether through the BIOSECURE Act or broader reshoring incentives, is a strategic allocation of manufacturing risk, and that is entirely rational.For LMS, this environment plays to our strengths. We have never positioned ourselves as a low-cost volume provider. Our competitive case is built on technical capability, regulatory reliability, and the ability to manage genuinely complex chemistry programs. Those attributes matter most to customers re-evaluating their supply relationships. Our investments in HPAPI containment, peptide building blocks, and integrated CDMO infrastructure reflect a deliberate commitment to being relevant precisely where complexity is highest. That is where we see sustained and growing demand, irrespective of how supply chain policy continues to evolve.How do you see the pharmaceutical landscape evolving over the next five years? How is LMS positioning itself to stay ahead of these changes?Five years from now, the defining feature of this industry will be the sheer scientific complexity embedded in pharmaceutical pipelines. Peptides, targeted oncology compounds, radiopharmaceuticals, these are not molecules you manufacture through conventional means. They demand deep process chemistry, specialized infrastructure, and partners who can genuinely co-develop solutions rather than simply execute a manufacturing order.That shift is changing how innovation-driven companies select their CDMO partners. Technical depth, regulatory track record, and the ability to navigate development risk have moved to the top of the evaluation criteria. At LMS, everything we are building right from our integrated CDMO block at Dabhasa to our HPAPI infrastructure at Vizag is calibrated to this reality. We are positioning to be a partner of choice and not just a transactional service provider.Could you provide an update on LMS’ oncology (HPAPI) manufacturing block in Visakhapatnam? How is it contributing to your CDMO strategy?Oncology manufacturing is one of the most technically exciting segments in the industry, and that complexity is only intensifying. As targeted therapies and antibody drug conjugates advance through pipelines, the demand for high-potency API capability delivered reliably, at global safety standards continues to grow.Our Vizag facility has been designed with that reality in mind, and that goes beyond containment engineering. It incorporates the process discipline, safety culture, and quality systems that high-potency manufacturing demands at every level of the organization. You cannot retrofit this kind of capability; it has to be purpose-built. What we have put in place is a platform that supports programs from early clinical development through commercial supply offering customers the continuity they need without transferring between sites as their programs mature. That continuity is a genuine competitive advantage.In December, LMS signed a strategic alliance with PolyPeptide Group AG to scale the global peptide supply chain. How will this collaboration strengthen your CDMO capabilities in the fast-growing peptide therapeutics segment?The rapid growth of peptide therapeutics, especially GLP1s, has fundamentally changed how the industry thinks about scale, reliability, and supply security. What was once a niche capability has become a core requirement, and customers are now looking for partners who can support the peptide value chain end-to-end, at a global scale.LMS’s strategy is built around serving the entire peptide market and establishing a globally competitive platform over the next three to five years, rooted in India, positioning itself as a credible partner amidst the China+1 strategy, capable of supporting both innovators and large pharmaceutical companies. The strategic alliance with PolyPeptide Group fits naturally within this vision allowing us to complement our own capabilities with additional synthesis depth and geographic flexibility, particularly for customers seeking resilient, diversified supply chains.LMS brings deep process chemistry expertise, a growing peptide intermediates and building blocks platform at Dabhasa, and strong regulatory execution. Importantly, as part of the Lupin group, we are also able to offer downstream drug product manufacturing capabilities spanning oral formulations as well as sterile injectables, including vials and drug-device delivery systems, which are increasingly critical as peptide programs move rapidly from development to commercial scale.Together, this integrated approach allows us to support customers across the full lifecycle, from peptide intermediates and APIs through to finished dosage forms. In a market defined by speed, scale, and supply assurance, this breadth of capability positions LMS to emerge as one of the leading global players in peptide CDMO services.As the industry convenes at DCAT Week, what is LMS bringing to the table this year?This year is about laying the foundations for LMS’s next phase of growth, particularly in complex and high value modalities. Strategically, our focus is on building the capabilities required to support emerging oncology and peptide adjacent platforms, while preparing for commercial scale-up over the next 18-24 months.On the technology side, LMS already has strong R&D capabilities across peptides, payloads and linkers, bioconjugation, and high potent compounds. These capabilities allow us to engage with customers early in development, solve complex chemistry challenges, and support rapid transition from discovery into development programs. Building on this base, we are progressing plans to establish commercial-scale GMP capacities in payload-linker synthesis and bioconjugation, including the development of a dedicated GMP facility in Vizag. This is a critical step for us as more antibody drug conjugates and related platforms move toward late-stage development and commercialization.Equally important is how we engage with customers. Alongside traditional CDMO models, we are increasingly offering alternative business models such as dedicated facilities, long-term capacity commitments, and guaranteed supply arrangements designed to address customers’ growing concerns around security, scalability, and speed to market. Overall, the year ahead is about execution including strengthening our R&D engine, advancing commercial-scale infrastructure, and deepening customer partnerships so that LMS is well positioned to support complex programs as they move into clinical and commercial reality.LMS has articulated its ambition to emerge as a trusted global CDMO partner with next-generation manufacturing capabilities and scientific agility. How would you assess your progress toward that goal?Trusted partnerships are earned over time, and I am clear-eyed about that. What I can say with confidence is that the strategic choices we have made over the past year have been the right ones, and the investment portfolio we have assembled aligns with direction the industry is heading.The development of our integrated CDMO block at Dabhasa, the scaling of peptide building blocks capabilities, the Vizag HPAPI facility, the PolyPeptide alliance, these reflect a coherent long-term strategy. What continues to occupy my attention most is execution. Infrastructure sets the stage, but it is our science, our quality systems, and our people that customers will ultimately judge us by. That work is ongoing, and it is where I spend most of my time.Could you update us on LMS’ green manufacturing initiatives? How is sustainability being integrated into your operations and facilities?Sustainability has shifted from a compliance requirement to a genuine competitive dimension, and I think that shift is permanent. Customers, investors, and regulators are asking harder questions, and organizations treating it just as a reporting exercise will find themselves at a disadvantage.Our approach remains grounded in the belief that durable environmental improvement comes from process intelligence. When you optimize synthesis routes for atom economy, reduce solvent intensity, and engineer waste out at the design stage, you improve sustainability and manufacturing economics simultaneously. These are not competing priorities. We are embedding green chemistry principles across our development workflows and investing in solvent recovery and waste management infrastructure. Our parent organization Lupin Limited was recently recognized among the top 1% of companies worldwide in the S&P Global Corporate Sustainability Assessment (CSA) attaining an overall score of 91 out of 100 establishing itself as the leading pharmaceutical company globally, and the leader across all sectors in India, surpassing both Indian and international peers which underscores our commitment.

    Impressions: 2255

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/we-re-investing-in-next-gen-cdmo-peptide-building-blocks-infrastructure-to-support-the-evolving-demands-of-complex-therapies

    PharmaCompass
    24 Mar 2026
    Share info Share

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/lupin-manufacturing-solutions-party-content-65016.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    CDMO Brochure

    read-more

      https://www.pharmacompass.com/pdf/party/content/lupin-manufacturing-solutions-party-content-7394.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Oncology Brochure

    read-more

      https://www.pharmacompass.com/pdf/party/content/lupin-manufacturing-solutions-party-content-41892.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    NEWS #PharmaBuzz

    read-more
    read-more
    Lupin Pharma's Manufacturing Arm Expands Dabhasa Facility
    Lupin Pharma's Manufacturing Arm Expands Dabhasa Facility

    20 Mar 2026

    // PRESS RELEASE

    https://www.lupin.com/media/press-releases/lupin-manufacturing-solutions-announces-expansion-of-manufacturing-facility-at-dabhasa-india

    PRESS RELEASE
    20 Mar 2026
    Share Share
    Lupin Manufacturing Solutions partners with PolyPeptide
    Lupin Manufacturing Solutions partners with PolyPeptide

    12 Dec 2025

    // PRESS RELEASE

    https://www.lupin.com/media/press-releases/lupin-manufacturing-solutions-and-polypeptide-announce-strategic-alliance-to-scale-global-peptide-supply-chain

    PRESS RELEASE
    12 Dec 2025
    Share Share
    Lupin Unit Expands CDMO Business With Oncology Block In Vizag
    Lupin Unit Expands CDMO Business With Oncology Block In Vizag

    12 Nov 2025

    // PRESS RELEASE

    https://www.lupin.com/lupin-manufacturing-solutions-unveils-dedicated-oncology-block-at-vizag-india/

    PRESS RELEASE
    12 Nov 2025
    Share Share
    LMS Empagliflozin API gets CADIFA approval from ANVISA, Brazil
    LMS Empagliflozin API gets CADIFA approval from ANVISA, Brazil

    24 Sep 2025

    // MEDICALDIALOGUES

    https://medicaldialogues.in/news/industry/pharma/lupin-manufacturing-solutions-empagliflozin-api-gets-cadifa-approval-from-anvisa-brazil-155251

    MEDICALDIALOGUES
    24 Sep 2025
    Share Share
    We are well-aligned to capitalize on the CDMO opportunity
    We are well-aligned to capitalize on the CDMO opportunity

    06 May 2025

    // PRESS RELEASE

    https://www.lupin.com/media/perspectives/we-are-expanding-our-cdmo-capabilities-to-meet-the-next-wave-of-complex-therapies-starting-with-oncology

    PRESS RELEASE
    06 May 2025
    Share Share
    AI& MLReshaping the Future of Pharma Manufacturing
    AI& MLReshaping the Future of Pharma Manufacturing

    13 Jan 2025

    // PRESS RELEASE

    https://www.lupin.com/media/perspectives/abdelaziz-toumi-interview-biovoice-news-jan-2025-issue-integration-of-ai-and-ml-to-play-a-critical-role-in-reshaping-pharma-manufacturing-operations

    PRESS RELEASE
    13 Jan 2025
    Share Share

    KEY PRODUCTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Sponsored Ads.
    full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    Services

    Discover the service capabilities from this company

    Analytical

    Discover their expertise for : Analytical

    API Manufacturing

    Discover their expertise for : API Manufacturing

    Drug Product Manufacturing

    Discover their expertise for : Drug Product Manufacturing

    API & Drug Product Development

    Discover their expertise for : API & Drug Product Development

    KEY SERVICES

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Pop up full-view
    Custom Synthesis and Process Development
    full-view
    Highly Potent API (HPAPI) Manufacturing
    full-view
    Process Development & Scale-Up
    full-view
    Small Molecule API Contract Manufacturing
    full-view

    Inspections and registrations

    Check the inspections & registration from this company

    ABOUT THIS PAGE

    Contact Lupin Manufacturing Solutions and get a quotation

    Lupin Manufacturing Solutions is a supplier offers 51 products (APIs, Excipients or Intermediates).

    Find Apremilast bulk with DMF, WC offered by Lupin Manufacturing Solutions

    Find Darunavir Ethanolate bulk with DMF, WC offered by Lupin Manufacturing Solutions

    Find Desvenlafaxine Succinate bulk with DMF, WC offered by Lupin Manufacturing Solutions

    Find Deutetrabenazine bulk with DMF, WC offered by Lupin Manufacturing Solutions

    Find Empagliflozin bulk with DMF, WC offered by Lupin Manufacturing Solutions

    Find Eslicarbazepine Acetate bulk with DMF, WC offered by Lupin Manufacturing Solutions

    Find Ferric Citrate bulk with DMF, WC offered by Lupin Manufacturing Solutions

    Find Migalastat bulk with DMF, WC offered by Lupin Manufacturing Solutions

    Find Mirabegron bulk with DMF, WC offered by Lupin Manufacturing Solutions

    Find Pirfenidone bulk with CEP, WC offered by Lupin Manufacturing Solutions

    Find Raltegravir Potassium bulk with DMF, WC offered by Lupin Manufacturing Solutions

    Find Rivaroxaban bulk with DMF, WC offered by Lupin Manufacturing Solutions

    Find Sevelamer Carbonate bulk with DMF, WC offered by Lupin Manufacturing Solutions

    Find Sevelamer Hydrochloride bulk with DMF, WC offered by Lupin Manufacturing Solutions

    Find Sitagliptin Phosphate bulk with DMF, WC offered by Lupin Manufacturing Solutions

    Find Sodium Zirconium Cyclosilicate bulk with DMF, WC offered by Lupin Manufacturing Solutions

    Find Apremilast bulk with DMF offered by Lupin Manufacturing Solutions

    Find Azilsartan Medoxomil Potassium bulk with DMF offered by Lupin Manufacturing Solutions

    Find Brivaracetam bulk with DMF offered by Lupin Manufacturing Solutions

    Find Cannabidiol bulk with DMF offered by Lupin Manufacturing Solutions

    Find Cysteamine Bitartrate bulk with DMF offered by Lupin Manufacturing Solutions

    Find Dapagliflozin bulk with DMF offered by Lupin Manufacturing Solutions

    Find Desvenlafaxine Benzoate bulk with WC offered by Lupin Manufacturing Solutions

    Find Dolutegravir Sodium bulk with DMF offered by Lupin Manufacturing Solutions

    Find Elagolix Sodium bulk with DMF offered by Lupin Manufacturing Solutions

    Find Ferric Citrate bulk with DMF offered by Lupin Manufacturing Solutions

    Find Glycerol Phenylbutyrate bulk with DMF offered by Lupin Manufacturing Solutions

    Find Iron Sucrose bulk with DMF offered by Lupin Manufacturing Solutions

    Find Ivacaftor bulk with DMF offered by Lupin Manufacturing Solutions

    Find Letermovir bulk with DMF offered by Lupin Manufacturing Solutions

    Find Lurasidone Hydrochloride bulk with DMF offered by Lupin Manufacturing Solutions

    Find Rufinamide bulk with DMF offered by Lupin Manufacturing Solutions

    Find Valbenazine Tosylate bulk with DMF offered by Lupin Manufacturing Solutions

    Find Venlafaxine Hydrochloride bulk with WC offered by Lupin Manufacturing Solutions

    Find Alectinib Hydrochloride bulk offered by Lupin Manufacturing Solutions

    Find Azithromycin Dihydrate bulk offered by Lupin Manufacturing Solutions

    Find Baloxavir Marboxil bulk offered by Lupin Manufacturing Solutions

    Find Bupropion Hydrochloride bulk offered by Lupin Manufacturing Solutions

    Find Cabotegravir bulk offered by Lupin Manufacturing Solutions

    Find Cholic Acid bulk offered by Lupin Manufacturing Solutions

    Find Dapagliflozin Propanediol Monohydrate bulk offered by Lupin Manufacturing Solutions

    Find Desvenlafaxine Benzoate bulk offered by Lupin Manufacturing Solutions

    Find Elexacaftor bulk offered by Lupin Manufacturing Solutions

    Find Ferric Carboxymaltose bulk offered by Lupin Manufacturing Solutions

    Find Ferumoxytol bulk offered by Lupin Manufacturing Solutions

    Find Olaparib bulk offered by Lupin Manufacturing Solutions

    Find Orforglipron Calcium Hydrate bulk offered by Lupin Manufacturing Solutions

    Find Piribedil bulk offered by Lupin Manufacturing Solutions

    Find Tetraferric tricitrate decahydrate bulk offered by Lupin Manufacturing Solutions

    Find Tezacaftor bulk offered by Lupin Manufacturing Solutions

    Find Tolvaptan bulk offered by Lupin Manufacturing Solutions

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search